Weight gain stopping/switch rules for antiretroviral clinical trials - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue AIDS. Official journal of the international AIDS Society Année : 2021

Weight gain stopping/switch rules for antiretroviral clinical trials

Résumé

Obesity develops in a substantial number of people initiating and maintaining modern antiretroviral therapy. The comorbidities associated with obesity make significant weight gain and metabolic changes a major consideration in clinical trials studying different regimens' potency and safety. It is as yet unclear what role individual antiretrovirals or classes play in weight gain but the issue is a complex one for clinical trial design, especially when deciding when "too much" weight has been gained, in a context where we do not yet know if switching to alternative regimens will slow, halt or reverse weight gain or metabolic changes. In addition, clinician and trial participant opinion on acceptable weight gain may differ. We offer preliminary guidance for discussion for future antiretroviral clinical trial design.
Fichier principal
Vignette du fichier
Weight_gain_stopping_switch_rules_for.10.pdf (139.6 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03636980 , version 1 (30-05-2022)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

W.D. Francois Venter, Simiso Sokhela, Alexandra Calmy, Luckyboy Mkhondwane, Bronwyn Bosch, et al.. Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS. Official journal of the international AIDS Society, 2021, 35 (Supplement 2), pp.S183-S188. ⟨10.1097/QAD.0000000000003092⟩. ⟨hal-03636980⟩
18 Consultations
35 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More